Medicon Village
Lund 223 81
Sweden
46 4 62 75 65 00
https://www.xintela.se
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 21
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Gregory Batcheller B.Sc., J.D., L.L.M., LLM | Executive Chairman of the Board | 383k | N/D | 1957 |
Dr. Evy Lundgren-Åkerlund Assoc.Prof, BSc, Ph.D. | Chief Executive Officer | 4,59M | N/D | 1957 |
Mr. Gunnar Telhammar | CFO & Finance Director | N/D | N/D | 1961 |
Ms. Lucienne Vonk | Chief Scientific Officer | N/D | N/D | N/D |
Dr. Per Goran Oskar Norlen | Chief Medical Officer | N/D | N/D | 1970 |
Camilla Wennersten | Director of Clinical Development | N/D | N/D | N/D |
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM that is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM, which is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies, such as TARG9 and TARG10, which are in preclinical study for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela AB (publ) was incorporated in 2009 and is based in Lund, Sweden.
L'ISS Governance QualityScore di Xintela AB (publ) al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.